Compare Becton Dickinson and Co (BDX) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Otis Worldwide Corp — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while Otis Worldwide Corp trades at $72.6 (market cap $27.84B). The key difference: Becton Dickinson and Co is the larger of the two by market cap, and Becton Dickinson and Co pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| BDX | OTIS | |
|---|---|---|
Market Cap | $41.51B | $27.84B |
Sector | Health | Industrials |
52-Week High | $185.39 | $101.07 |
52-Week Low | $135.49 | $69.34 |
Enterprise Value | $57.97B | $35.23B |
Dividend Yield | 2.79% | 2.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Otis Worldwide trades at $73.42, up 0.45% today, with a bullish technical signal from moving averages but mixed quarterly earnings. The company maintains stable revenue near $14.4B (2025) and a net margin of 10.11%, supported by service growth and modernization initiatives like recent upgrades at Christ the Redeemer in Brazil. Cash flow from operations remains strong at $1.6B, though net cash flow turned negative in 2025 due to financing activities.
The stock offers 24% upside to the consensus price target of $91.00, with analysts divided (38% Buy, 54% Hold). Risks include debt levels (75.54% debt-to-asset ratio) and margin pressure from tariffs, but dividend growth (5% increase to $0.44) and buybacks provide shareholder value. Near-term performance hinges on Q2 2026 earnings due July 22, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
